EFFICACY AND SAFETY OUTCOMES OFTAK-279, A SELECTIVE ORAL TYROSINE KINASE 2 (TYK2) INHIBITOR, FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2BTRIAL IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS

Authors
Category Primary study
JournalANNALS OF THE RHEUMATIC DISEASES
Year 2024
This article has no abstract
Epistemonikos ID: c2e4f95e65796c3cdb99ccbe17b0154f3ae9ecfa
First added on: Feb 18, 2025